JO3628B1 - كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1 - Google Patents

كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1

Info

Publication number
JO3628B1
JO3628B1 JOP/2015/0058A JOP20150058A JO3628B1 JO 3628 B1 JO3628 B1 JO 3628B1 JO P20150058 A JOP20150058 A JO P20150058A JO 3628 B1 JO3628 B1 JO 3628B1
Authority
JO
Jordan
Prior art keywords
thf
amines
pde1
inhibitors
halogenated
Prior art date
Application number
JOP/2015/0058A
Other languages
English (en)
Inventor
Kyhn Rasmussen Lars
Kehler Jan
Langgard Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of JO3628B1 publication Critical patent/JO3628B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم كوينازولين مهلجن-THF-أمينات على هيئة مثبطات PDE1 واستخدامها على هيئة دواء، بالتحديد لمعالجة اضطرابات تنكسية عصبية والاضطرابات النفسية.
JOP/2015/0058A 2014-04-04 2015-03-30 كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1 JO3628B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04

Publications (1)

Publication Number Publication Date
JO3628B1 true JO3628B1 (ar) 2020-08-27

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0058A JO3628B1 (ar) 2014-04-04 2015-03-30 كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1

Country Status (39)

Country Link
US (2) US10005764B2 (ar)
EP (1) EP3126354B1 (ar)
JP (1) JP6554116B2 (ar)
KR (1) KR20160138084A (ar)
CN (2) CN106132953B (ar)
AP (1) AP2016009521A0 (ar)
AR (1) AR101155A1 (ar)
AU (1) AU2015239696B2 (ar)
CA (1) CA2943011A1 (ar)
CL (1) CL2016002515A1 (ar)
CR (1) CR20160463A (ar)
CY (1) CY1122784T1 (ar)
DK (1) DK3126354T3 (ar)
DO (1) DOP2016000263A (ar)
EA (1) EA032579B1 (ar)
EC (1) ECSP16082599A (ar)
ES (1) ES2776359T3 (ar)
GE (2) GEAP201814286A (ar)
GT (1) GT201600213A (ar)
HR (1) HRP20200369T1 (ar)
IL (1) IL248078B (ar)
JO (1) JO3628B1 (ar)
LT (1) LT3126354T (ar)
MA (1) MA39837B1 (ar)
MX (1) MX364519B (ar)
PE (1) PE20161380A1 (ar)
PH (1) PH12016501938A1 (ar)
PL (1) PL3126354T3 (ar)
PT (1) PT3126354T (ar)
RS (1) RS60017B1 (ar)
RU (1) RU2692808C2 (ar)
SG (1) SG11201608190YA (ar)
SI (1) SI3126354T1 (ar)
SM (1) SMT202000132T1 (ar)
SV (1) SV2016005297A (ar)
TW (1) TWI664178B (ar)
UA (1) UA119166C2 (ar)
WO (1) WO2015150254A1 (ar)
ZA (1) ZA201606566B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132953B (zh) 2014-04-04 2019-03-22 H.隆德贝克有限公司 作为pde1抑制剂的卤化的喹唑啉-thf-胺
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
KR20210013214A (ko) 2018-05-25 2021-02-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2020210614A1 (en) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
CN1784391B (zh) * 2003-03-03 2010-06-09 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
WO2007096743A1 (en) * 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2013505909A (ja) * 2009-09-24 2013-02-21 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物害虫を駆除するためのアミノキナゾリン化合物
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
AU2015239537B2 (en) 2014-04-04 2019-04-04 Eidgenoessische Technische Hochschule Zuerich 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
EP3126359A1 (en) 2014-04-04 2017-02-08 F. Hoffmann-La Roche AG Pyridine-2-amides useful as cb2 agonists
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CN106132953B (zh) 2014-04-04 2019-03-22 H.隆德贝克有限公司 作为pde1抑制剂的卤化的喹唑啉-thf-胺
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors

Also Published As

Publication number Publication date
EP3126354A1 (en) 2017-02-08
MX364519B (es) 2019-04-30
EA201691773A1 (ru) 2017-01-30
CA2943011A1 (en) 2015-10-08
SV2016005297A (es) 2016-11-30
ZA201606566B (en) 2017-11-29
PL3126354T3 (pl) 2020-06-15
JP2017509680A (ja) 2017-04-06
KR20160138084A (ko) 2016-12-02
UA119166C2 (uk) 2019-05-10
CR20160463A (es) 2017-03-06
CN106132953B (zh) 2019-03-22
ECSP16082599A (es) 2017-02-24
MX2016012955A (es) 2016-12-07
TW201620901A (zh) 2016-06-16
CN109999039A (zh) 2019-07-12
DOP2016000263A (es) 2016-11-30
PE20161380A1 (es) 2017-01-15
LT3126354T (lt) 2020-03-25
GEP20186920B (en) 2018-11-12
SMT202000132T1 (it) 2020-05-08
ES2776359T3 (es) 2020-07-30
CN106132953A (zh) 2016-11-16
MA39837B1 (fr) 2020-05-29
WO2015150254A1 (en) 2015-10-08
US20190144434A1 (en) 2019-05-16
RU2692808C2 (ru) 2019-06-27
US10005764B2 (en) 2018-06-26
AU2015239696B2 (en) 2019-10-24
GEAP201814286A (en) 2018-06-11
RU2016138743A3 (ar) 2019-01-15
AP2016009521A0 (en) 2016-10-31
HRP20200369T1 (hr) 2020-08-07
DK3126354T3 (da) 2020-03-09
RS60017B1 (sr) 2020-04-30
US20170022186A1 (en) 2017-01-26
JP6554116B2 (ja) 2019-07-31
CY1122784T1 (el) 2021-05-05
TWI664178B (zh) 2019-07-01
CL2016002515A1 (es) 2016-12-16
SG11201608190YA (en) 2016-10-28
EP3126354B1 (en) 2020-01-22
SI3126354T1 (sl) 2020-04-30
EA032579B1 (ru) 2019-06-28
US10526319B2 (en) 2020-01-07
PT3126354T (pt) 2020-03-17
PH12016501938A1 (en) 2017-02-06
RU2016138743A (ru) 2018-05-07
AR101155A1 (es) 2016-11-30
GT201600213A (es) 2019-07-29
AU2015239696A1 (en) 2016-10-06
IL248078B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12017500602A1 (en) Methods for treating ocular conditions
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents